Baseline characteristics of study participants
| Variable | Intervention | Control |
| Site | n=170 | n=188 |
| Vancouver | 102 (60.0) | 107 (56.9) |
| New Westminster | 68 (40.0) | 81 (43.1) |
| Gender | n=170 | n=188 |
| Female | 90 (52.9) | 106 (56.4) |
| Male | 80 (47.1) | 81 (43.1) |
| Transgender | 0 | 1 (0.5) |
| Age | ||
| Median (IQR) age in years | 45 (34–55) | 42 (33–50) |
| Alcohol use | n=154 | n=181 |
| None | 90 (58.4) | 107 (59.1) |
| 1–2 times monthly | 46 (29.9) | 56 (30.9) |
| 2–3 times weekly | 15 (9.7) | 15 (8.3) |
| Daily | 3 (2.0) | 3 (1.7) |
| Recreational drug use | n=155 | n=172 |
| None | 149 (96.1) | 167 (97.1) |
| 1–2 times monthly | 3 (1.9) | 2 (1.1) |
| 2–3 times weekly | 2 (1.3) | 1 (0.6) |
| Daily | 1 (0.7) | 2 (1.2) |
| Highest level of education attained | n=154 | n=181 |
| No formal education | 3 (2.0) | 1 (0.6) |
| Elementary or junior high school | 6 (3.9) | 3 (1.7) |
| High school | 29 (18.8) | 31 (17.1) |
| College/trade school | 57 (37.0) | 71 (39.2) |
| University | 59 (38.3) | 75 (41.4) |
| Average annual income $CAN | n=127 | n=158 |
| <10 000 | 18 (14.2) | 40 (25.3) |
| 10 000–49 999 | 77 (60.6) | 85 (53.8) |
| 50 000–99 999 | 28 (22.1) | 30 (19.0) |
| >100 000 | 4 (3.2) | 3 (1.9) |
| Region of birth | n=168 | n=187 |
| Southeast Asia and Oceania | 61 (36.3) | 68 (36.4) |
| South Asia and the Middle East | 35 (20.8) | 38 (20.3) |
| Canada/USA | 27 (16.1) | 38 (20.3) |
| Eastern Asia | 25 (14.9) | 27 (14.4) |
| Africa | 13 (7.7) | 8 (4.3) |
| Europe | 3 (1.8) | 6 (3.2) |
| Central America | 4 (2.4) | 2 (1.1) |
| Treatment regimen | n=170 | n=188 |
| 9INH | 114 (67.1) | 132 (70.2) |
| 4RIF | 56 (32.9) | 56 (29.8) |
Data are presented as n (%), unless otherwise stated. IQR: Interquartile range; 9INH: 9 months of daily isoniazid; 4RIF: 4 months daily rifampin.